MT-7117 Low Dose ( DrugBank: - )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
254	ポルフィリン症	2

254. ポルフィリン症

---

臨床試験数 : 70 /  薬物数 : 54 - (DrugBank : 19) / 標的遺伝子数 : 19 - 標的パスウェイ数 : 35

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04402489 (ClinicalTrials.gov)	June 1, 2020	20/5/2020	Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoetic Protoporphyria or X-Linked Protoporphyria	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Adults and Adolescents With Erythropoietic Protoporphyria or X-Linked Protoporphyria	EPP;XLP	Drug: Placebo;Drug: MT-7117 Low Dose;Drug: MT-7117 High Dose	Mitsubishi Tanabe Pharma Development America, Inc.	NULL	Active, not recruiting	12 Years	75 Years	All	184	Phase 3	United States;Australia;Canada;Germany;Italy;Japan;Norway;Spain;Sweden;United Kingdom;Finland
2	NCT03520036 (ClinicalTrials.gov)	July 5, 2018	23/4/2018	Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria	A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria	Erythropoietic Protoporphyria (EPP)	Drug: MT-7117 low dose;Drug: MT-7117 high dose;Drug: Placebo	Mitsubishi Tanabe Pharma Development America, Inc.	NULL	Completed	18 Years	75 Years	All	102	Phase 2	United States